Tata Memorial Centre and ACTREC Study Reveals High Cost of Modern Cancer Drugs Unaffordable for Most in India and Globally for treatment of Head and Neck Cancer

**Executive Summary** A study published in the journal Head & Neck by Tata Memorial Centre and ACTREC reveals that modern cancer drugs, particularly immunotherapies for head and neck cancer, are prohibitively expensive for most individuals in India and globally. Key findings indicate significant affordability issues with drugs like pembrolizumab and nivolumab, with a 6-month course of pembrolizumab costing approximately 80 times the average monthly income in India. The study, released on March 2, 2026, highlights the need for pricing reforms and more cost-effective treatment strategies. **Key Points / Main Content** * **Drug Affordability Crisis:** * Modern cancer medicines, especially immunotherapies for head and neck cancer, are extremely costly worldwide, rendering them unaffordable for the majority of families, including in India. * In India, a six-month course of pembrolizumab costs nearly 80 times the average monthly income, and nivolumab costs over 20 times the average monthly income. * Similar unaffordability issues are prevalent in Pakistan and Bangladesh. * Even in developed countries like the US and UK, these drugs impose significant financial burdens. * The cost of one pembrolizumab patient in India could fund treatment for 18-22 patients using lower-cost targeted therapies. * **Treatment Efficacy vs. Cost:** * While newer drugs offer survival benefits for some head and neck cancer patients, their limited efficacy does not always justify the high costs. * High treatment costs can push families into poverty, emphasizing the need for prevention and early detection. * **Recommendations and Calls to Action:** * Researchers urge judicious use of expensive drugs based on strong evidence, prioritizing patients most likely to benefit. * There is a call for research into cost-effective, context-specific treatments. * Promotion of high-quality generics and biosimilars with rigorous quality checks and regulatory oversight is recommended. * Deeper pricing reforms are deemed essential, including stronger negotiations and better insurance. * Emphasis is placed on prevention through tobacco, areca nut, and alcohol control, alongside early screening. * **Study Details:** * The study titled "Disparity in the Markers of Affordability Across Targeted- and Immune-Therapy Drugs Used in Head and Neck Cancers" was published in the journal Head & Neck (2026). **Impact Analysis** **Patients** * **Impact:** Patients face extreme financial burdens due to the high cost of modern cancer drugs, potentially leading to poverty and limiting access to potentially life-saving treatments. Many rely on personal savings for treatment. * **Action Required:** Patients need access to more affordable treatment options and potentially financial assistance or improved insurance coverage to manage treatment costs. **Healthcare Providers (e.g., Tata Memorial Centre, ACTREC)** * **Impact:** Healthcare providers are at the forefront of treating patients struggling with unaffordable drug costs and are involved in research and recommendations for better treatment strategies. * **Action Required:** Healthcare providers should continue to advocate for pricing reforms, judiciously prescribe expensive drugs based on evidence, and explore and implement cost-effective treatment alternatives. **Government and Policymakers** * **Impact:** The study highlights a critical gap in healthcare accessibility, particularly concerning cancer treatment costs, which necessitates policy intervention. * **Action Required:** Policymakers need to implement deeper pricing reforms, enhance insurance schemes, strengthen negotiations with pharmaceutical companies, and reinforce prevention strategies for head and neck cancer. They should also support the development and regulation of high-quality generics and biosimilars. **Pharmaceutical Companies** * **Impact:** The study indirectly scrutinizes the pricing of their advanced cancer drugs, suggesting a need to re-evaluate pricing strategies in relation to patient affordability and treatment benefit. * **Action Required:** Pharmaceutical companies may need to consider more accessible pricing models, especially in lower-income settings, and engage in discussions regarding drug pricing reforms.

Key Entities Referenced